Kalaris Therapeutics Inc Dossier - Source-backed chat

Kalaris Therapeutics Inc

KLRSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.45

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.85Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $67.8M

Enterprise Value $24.7M

Shares Outstanding 23.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kalaris Therapeutics (NASDAQ: KLRS) is a clinical-stage biopharmaceutical company focused on developing TH103, a novel dual-targeting VEGF/HSPG biologic designed for extended intraocular retention and enhanced VEGF inhibition. Developed by VEGF pioneer Dr. Napoleone Ferrara, TH103 targets a massive and growing retinal disease market (wet AMD, DME, RVO). Following its strategic reverse merger with AlloVir in March 2025, Kalaris secured a robust cash runway of $104.9 million (as of Q1 2026), which is expected to fund operations into Q4 2027. This capital runway fully covers the critical Phase 1b/2 clinical data readout expected in 1H 2027, making Kalaris an attractive high-upside biotechnology play with a validated scientific pedigree.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$18.71

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0015%

The Phase 1b/2 trial reveals safety concerns, such as recurring or severe intraocular inflammation, or fails to demonstrate a meaningful durability advantage over existing standard-of-care therapies (like Eylea or Vabysmo). This limits the commercial viability of TH103, delays or halts the Phase 3 program, and forces Kalaris to restructure or seek alternative strategic options as its cash runway depletes toward late 2027.

Base CaseCentral scenario

$18.7150%

Matches the consensus mean

TH103 meets its primary safety and efficacy endpoints in the Phase 1b/2 trial, showing competitive visual acuity gains and anatomical improvements with a durability profile that supports a 12-to-16-week dosing regimen. Kalaris successfully initiates Phase 3 trials by year-end 2027, utilizing its existing cash runway and potentially raising additional capital through its $100 million ATM program to support late-stage development.

Bull CaseUpside scenario

$25.0035%

TH103 demonstrates superior durability and efficacy in the Phase 1b/2 trial compared to market-leading anti-VEGF agents, showing extended treatment intervals (e.g., 16 weeks or longer) without safety concerns. This triggers a rapid transition to Phase 3 trials by late 2027, attracting major pharmaceutical partnerships and positioning Kalaris to capture a significant share of the multi-billion dollar retinal disease market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong scientific pedigree with TH103 engineered by Dr. Napoleone Ferrara, a pioneer of anti-VEGF therapy (inventor of Avastin and Lucentis).
Differentiated dual-targeting mechanism (VEGF/HSPG anchoring) designed to achieve extended intraocular retention and reduce patient injection burden.
Robust balance sheet with $104.9 million in cash and marketable securities (as of March 31, 2026), providing a runway into Q4 2027 and through key clinical milestones.
Clear clinical development path with Phase 1b/2 data expected in 1H 2027 and Phase 3 trials planned for late 2027.

Key Investment Risks

Clinical development risk inherent to early-stage biopharmaceutical assets, with potential for safety issues (e.g., intraocular inflammation) or lack of efficacy.
Intense competition in the retinal disease space from established blockbusters (Eylea, Vabysmo) and other pipeline candidates.
High operational cash burn typical of clinical-stage biotechs, which will accelerate as patient enrollment escalates and Phase 3 trials approach.

Thesis Invalidation Triggers

Failure of TH103 to meet safety or efficacy endpoints in the Phase 1b/2 clinical trial.
Unacceptable rates of serious adverse events, such as severe intraocular inflammation or systemic safety signals.
Significant delays in clinical trial timelines, pushing the Phase 1b/2 readout beyond 1H 2027 or delaying Phase 3 initiation past 2027.
Severe cash burn acceleration that depletes the company's capital runway significantly ahead of Q4 2027 without access to additional funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.